Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegdinetanib vs Bevacizumab in First-Line Non-Squamous NSCLC
NCT00850577Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2009
- Primary completion
- Aug 2013
- Countries
- 8
01
Overview
A Phase 2 trial of pegdinetanib in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Jun 2009; status: terminated.
02
Drugs
pegdinetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00850577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850577.